IDO1 regulating ROS rhythm reveals glycogenolysis/PPP as a cancer treatment target.

Disruption of ROS rhythmicity through dual inhibition of IDO1 and AhR extends survival in cancer models, revealing a new therapeutic approach targeting tumor oxidative balance.

• Why it matters: Understanding how ROS rhythms influence tumor growth and treatment response is crucial, as their dysregulation is linked to tumor progression and therapy resistance.
• What they did: The study examined ROS oscillations in cancer cells and tumor samples, focusing on IDO1's role in regulating ROS clearance via metabolic pathways, and tested combined inhibition of IDO1 and AhR in mice.
• The result: Blocking both IDO1 and AhR significantly prolongs survival, suggesting that targeting ROS rhythm disruption can be an effective strategy to hinder tumor growth and improve therapeutic outcomes.